Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.65 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.65 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.65 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.65 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.65 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.64 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.64 |
| ▸ | FAAH | O00519 | 2/20 | 0.59 |
| ▸ | CHRND | Q07001 | 6/20 | 0.58 |
| ▸ | CHRNA1 | P02708 | 2/20 | 0.58 |
| ▸ | CHRNG | P07510 | 2/20 | 0.58 |
| ▸ | CHRNB1 | P11230 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21356921 | 1.00 | CHRNB2 (0.65) | CHRNB2CHRNB4CHRNA3CHRNA4PTPN1 | |
| SCHEMBL21356920 | 1.00 | CHRNB2 (0.65) | CHRNB2CHRNB4CHRNA3CHRNA4PTPN1 | |
| SCHEMBL6438848 | 0.96 | CHRNB2 (0.69) | CHRNB2CHRNB4CHRNA3CHRNA4PTPN1 | |
| SCHEMBL9519035 | 0.96 | CHRNB2 (0.69) | CHRNB2CHRNB4CHRNA3CHRNA4PTPN1 | |
| SCHEMBL23086284 | 0.94 | PTPN1 (0.68) | CHRNB2CHRNB4CHRNA3CHRNA4PTPN1 | |
| SCHEMBL16247369 | 0.94 | CHRNB2 (0.69) | CHRNB2CHRNB4CHRNA3CHRNA4PTPN1 | |
| SCHEMBL12324830 | 0.94 | CHRNB2 (0.69) | CHRNB2CHRNB4CHRNA3CHRNA4PTPN1 | |
| SCHEMBL988166 | 0.90 | CHRNB2 (0.77) | CHRNB2CHRNB4CHRNA3CHRNA4GRIA1 | |
| SCHEMBL5817448 | 0.90 | FAAH (0.71) | CHRNB2CHRNB4CHRNA3CHRNA4PTPN1 | |
| SCHEMBL21346955 | 0.89 | GRIA1 (0.74) | GRIA1CHRNDCHRNA1CHRNGCHRNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3454663-B1 | LOW MOLECULAR WEIGHT ORGANIC GELATORS OF VEGETABLE OIL | RUDJER BOSKOVIC INST (HR) | 2024-12-11 | — | — | EP | disclosed |
| US-20190281853-A1 | LOW MOLECULAR WEIGHT ORGANIC GELATORS OF VEGETABLE OIL | RUDJER BOSKOVIC INSTITUTE (HR) | 2019-09-19 | — | — | US | disclosed |
| WO-2008102127-A2 | GEL FORMING COMPOUNDS | PLIVA HRVATSKA D.O.O. (HR) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190281853-A1 | LOW MOLECULAR WEIGHT ORGANIC GELATORS OF VEGETABLE OIL | ACP1, ELOVL1, ELOVL3 | CHRNB2 4642/4885CHRNB4 4796/4885CHRNA3 4344/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.